Amendments to the Claims:

Please cancel claims 2, 3, 12 and 13 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application. Please amend claims 1 and 11 as indicated below.

1. (Currently amended) A method for determining whether a subject has a defect in cell proliferation, comprising assaying a diagnostic sample of the subject for GLUTx expression, wherein detection of GLUTx expression elevated above normal is diagnostic of a defect in cell proliferation, wherein the defect in cell proliferation is a mammary adenocarcinoma or an endometrial adenocarcinoma, ~~hyperplasia, a pre-neoplastic lesion or a neoplasm,~~ wherein the diagnostic sample is assayed using an agent reactive with GLUTx protein or using at least one nucleic acid probe which hybridizes to nucleic acid encoding GLUTx protein, and wherein GLUTx protein has the amino acid sequence set forth in SEQ ID NO:1.

2.-3. (Canceled)

4. (Original) The method of Claim 1, wherein the diagnostic sample is assayed using an agent reactive with GLUTx.

5. (Original) The method of Claim 4, wherein the agent is labeled with a detectable marker.

6. (Original) The method of Claim 4, wherein the agent is an antibody.

7. (Original) The method of Claim 6, wherein the antibody is labeled with a detectable marker.

8. (Original) The method of Claim 1, wherein the diagnostic sample is assayed using at least one nucleic acid probe which hybridizes to nucleic acid encoding GLUTx.

9. (Original) The method of Claim 8, wherein the nucleic acid probe is DNA or RNA.

10. (Original) The method of Claim 9, wherein the nucleic acid probe is labeled with a detectable marker.

11. (Currently amended) A method for assessing the efficacy of therapy to treat a defect in cell proliferation in a subject who has undergone or is undergoing treatment for a defect in cell proliferation, comprising assaying a diagnostic sample of the subject for GLUTx expression, wherein detection of GLUTx expression elevated above normal in the diagnostic sample is indicative of a need to continue therapy to treat the defect in cell proliferation, and normal GLUTx expression in the diagnostic sample is indicative of successful therapy, wherein the defect in cell proliferation is a mammary adenocarcinoma or an endometrial adenocarcinoma, ~~hyperplasia, a pre-neoplastic lesion or a neoplasm,~~ wherein the diagnostic sample is assayed using an agent reactive with GLUTx protein or using at least one nucleic acid probe which hybridizes to nucleic acid encoding GLUTx protein, and wherein GLUTx protein has the amino acid sequence set forth in SEQ ID NO:1.

12.-13. (Canceled)

14. (Original) The method of Claim 11, wherein the diagnostic sample is assayed using an agent reactive with GLUTx.

15. (Original) The method of Claim 14, wherein the agent is labeled with a detectable marker.

16. (Original) The method of Claim 14, wherein the agent is an antibody.

17. (Original) The method of Claim 16, wherein the antibody is labeled with a detectable marker.

18. (Original) The method of Claim 11, wherein the diagnostic sample is assayed using at least one nucleic acid probe which hybridizes to nucleic acid encoding GLUTx.

19. (Original) The method of Claim 18, wherein the nucleic acid probe is DNA or RNA.

20. (Original) The method of Claim 19, wherein the nucleic acid probe is labeled with a detectable marker.

21.-35. (Canceled)